CN113694080B - Antiviral application of common sage herb polysaccharide - Google Patents
Antiviral application of common sage herb polysaccharide Download PDFInfo
- Publication number
- CN113694080B CN113694080B CN202110940901.9A CN202110940901A CN113694080B CN 113694080 B CN113694080 B CN 113694080B CN 202110940901 A CN202110940901 A CN 202110940901A CN 113694080 B CN113694080 B CN 113694080B
- Authority
- CN
- China
- Prior art keywords
- polysaccharide
- porcine pseudorabies
- pseudorabies virus
- common sage
- virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses an antiviral application of common sage herb polysaccharide, which is prepared from common sage herbSalvia plebeiaR.br.) from the whole plant. The virus is anti-porcine pseudorabies virus, and the litchis polysaccharide inhibits the adsorption, encytosis and replication of the porcine pseudorabies virus by reducing cytopathic effect caused by the porcine pseudorabies virus, so that the porcine pseudorabies virus is killed. The invention also provides an antiviral preparation, wherein the common sage herb polysaccharide is dissolved in PBS buffer solution or DMSO with the concentration of 0.05-0.20 mol/L to obtain solution with the concentration of 200-800 mu g/mL, and the aqueous solution has good prevention and treatment effect on porcine Pseudorabies virus (PrV), and is an ideal biological veterinary drug for developing high-efficiency, green and ecological agriculture.
Description
Technical Field
The invention relates to a new application of common sage herb polysaccharide in preparing antiviral drugs.
Background
The porcine Pseudorabies virus (PrV) belongs to the herpesviridae family, is similar to other herpesviruses, has latent infection on various nervous tissues of pigs under normal conditions, can cause various livestock and wild animals to generate heat, can cause acute infectious diseases with extreme itch (except pigs) and encephalomyelitis as main symptoms, is fulminant epidemic, can cause abortion, stillbirth and boar sterility of pregnant sows, mass death of newborn piglets, dyspnea and growth arrest of fattening pigs and the like, is one of important infectious diseases which harm the global pig industry, and is particularly important for preventing and controlling the spread of the virus in livestock.
At present, the drugs applied to resisting the porcine pseudorabies virus are mainly antiviral biological agents and western medicines. However, there is no drug that interferes with the host cell metabolism and only interferes with virus replication or directly kills viruses, and some viruses have drug resistance to antiviral drugs, and even have drug-dependent variations, which makes antiviral drugs not effective. The Chinese herbal medicine has less toxic and side effects and less residue, and has the advantages which cannot be achieved by western medicines in the aspect of antivirus. Many experiments show that the Chinese herbal medicine can interfere virus replication, and can play an antiviral role by regulating the immunity of an organism and the nonspecific anti-inflammatory reaction.
Common sage herb is the whole grass of common sage herb Salvia plebeia R.Br. of the genus Salvia of the family Labiatae, also called as evening primrose, chinese forest frog grass, wrinkled gianthyssop herb, and the like, is mainly produced in Jiangsu, zhejiang, anhui, henan, shandong and the like, has rich resources, is firstly carried in compendium of materia medica, mainly contains polysaccharides, terpenoids, flavonoids, phenylpropanoids and volatile oils in chemical components, has pharmacological activities of antibiosis, anti-inflammation, antioxidation and the like, and is mainly used for treating amygdalitis, bronchitis, metrorrhagia, hematochezia, nephritic edema and the like. In the aspect of application of antiviral veterinary drugs, only a compound veterinary drug patent application of liujiakui and the like, namely antiviral veterinary drug liquid and a preparation method thereof (application number: 201811238488.6), is disclosed, the antiviral veterinary drug liquid is prepared by adopting various compound components of decoquinate, radix isatidis, honeysuckle, liquorice, radix bupleuri, radix astragali, white hyacinth beans, acanthopanax, honeysuckle stem, common sage herb and the like, but the active ingredients of the antiviral veterinary drug liquid are undefined, the types of viruses inhibited by the veterinary drug are not defined, the added radix isatidis, honeysuckle, liquorice, radix bupleuri and the like have obvious antiviral effects, the addition of the decoquinate can play a synergistic effect with important antiviral active ingredients to improve the effect of the finished product liquid, and the antiviral effect of common sage herb is not defined, and the lactobacillus fermentation liquid of the common sage herb extracting solution is adopted in the compound veterinary drug. In the method of publication No. CN102083415A, entitled method for treating herpes virus infection, there is provided topical application of a nanoemulsion composition having antiviral or virustatic properties against herpes viruses, which comprises an antiviral main drug and other pharmaceutical adjuvants, in the oil in the preparation of the nanoemulsion, oil of common sage leaf is used as an alternative oil, but its use is only as an oil phase.
So far, no report of the application of the salvia plebeian polysaccharide to the livestock-type transmitted diseases caused by the porcine pseudorabies virus exists.
Disclosure of Invention
In order to overcome the defects of the prior art, the invention aims to provide a new antiviral application of common sage herb polysaccharide.
The virus is porcine pseudorabies virus resistant. The action mechanism is that the litchis polysaccharide can reduce cytopathic effect caused by the porcine pseudorabies virus, inhibit the adsorption, cell entry and replication of the porcine pseudorabies virus and directly kill the porcine pseudorabies virus.
The common sage herb is the whole herb of common sage herb Salvia plebeia R.Br.
The invention provides a preparation for preventing or treating porcine pseudorabies virus infection, which comprises solid substances obtained by extracting common sage herb polysaccharide by a hot boiling method with water as a solvent and precipitating with ethanol.
The content of the common sage herb polysaccharide solid in the preparation is 200-800 mug/mL, preferably 400-600 mug/mL, and more preferably 600 mug/mL.
The preparation is obtained by dissolving the obtained common sage herb polysaccharide in a buffer solution, and the adopted solvent is PBS buffer solution or DMSO;
the concentration of the PBS buffer solution is 0.05-0.20 mol/L, and the better concentration is 0.10-0.12 mol/L.
The invention has the beneficial effects that the litchi chinensis grass polysaccharide has an antiviral effect on the porcine pseudorabies virus, inhibits the adsorption, encytosis and replication of the porcine pseudorabies virus by reducing cytopathic effect caused by the porcine pseudorabies virus, has small environmental pollution and has no toxic or side effect on animals.
Drawings
FIG. 1 shows the standard curve and results of the measurement of the content of common sage herb polysaccharide, as shown in FIG. 1, the concentration of the glucose standard solution is in a good linear relationship with the absorbance (A: absorbance, C: concentration of the glucose standard solution) within the range of 10-50 mg/L;
FIG. 2 is a linear relationship diagram of the virus inhibition effect of common sage herb polysaccharide.
Detailed Description
The technical solutions provided by the present invention are described in detail below with reference to examples, but they should not be construed as limiting the scope of the present invention.
Example 1
Preparation of solid sage polysaccharide (reference: wanaya, tian \31054; \\3130, huangjun Lin, et al., common sage Total polysaccharide extraction Process research [ J ]. Guangzhou chemical engineering, 2018,046 (010): 75-77)
(1) Weighing 20g of common sage herb, cutting into pieces, putting into a 1000mL beaker, adding 500mL of water, heating, boiling for 1-2 h (in the reference document, the heating temperature is not more than 90 ℃, the temperature is increased to facilitate more complete extraction), filtering, removing filter residues, distilling to remove part of water to obtain 100mL of common sage herb water extract solution, and cooling to room temperature.
(2) Adding 400mL of absolute ethanol to precipitate the polysaccharide in the solution, then placing the solution in a refrigerator at 4 ℃ for standing overnight, filtering, and drying to obtain crude polysaccharide. ( The reference does not have this step. This step helps to remove impurities from the polysaccharide )
(3) The crude polysaccharide was dissolved in 50mL of hot water, and the solution after dissolution was subjected to deproteinization by adding Savage reagent (chloroform: n-butanol = 4).
(4) And (3) fully and uniformly mixing the dissolved liquid with a Savage reagent, carrying out suction filtration, and carrying out freeze drying to obtain 4.28g of common sage herb polysaccharide.
Example 2
Determination of polysaccharide content of Salvia plebeia (reference: wanya, tian \31054; \31310, huangjunlin, et al., total polysaccharide extraction of Salvia plebeia [ J ]. Guangzhou chemical, 2018,046 (010): 75-77)
(1) Preparation of glucose standard solution: accurately weighing 1.0100g of a glucose analytical pure sample, adding a small amount of deionized water for dissolving, and metering the volume to a 100mL volumetric flask to obtain a glucose standard solution with the concentration of 0.1000 g/L.
(2) Preparation of a standard curve: precisely measuring 0.2 mL, 0.4 mL, 0.6 mL, 0.8 mL and 1.0mL of glucose standard solution respectively, placing the glucose standard solution into test tubes, adding distilled water into each test tube to 2.0mL, adding 1mL of 5% phenol solution, fully and uniformly mixing the solution, dropwise adding 5mL of concentrated sulfuric acid, uniformly mixing, standing for 5min, placing the solution into a 55 ℃ water bath, heating for 15min, taking out, naturally cooling for 5min to terminate the reaction, rapidly measuring, measuring the absorbance (A) at 490nm by adopting a UV method, taking the distilled water as a blank control, finally drawing a standard curve by taking the glucose concentration as an abscissa and the absorbance as an ordinate to obtain a glucose linear equation, wherein the glucose linear equation is shown in figure 1.
(3) Preparation of a sample solution: taking 1.0g of crude polysaccharide sample, adding distilled water to dissolve the crude polysaccharide sample, and fixing the volume to a 100mL volumetric flask to obtain a crude polysaccharide sample solution with the concentration of 0.1 g/L. Adding 0.25mL of crude polysaccharide sample solution into a test tube, adding distilled water to 2.0mL, adding 1mL of 5% phenol solution, fully and uniformly mixing the solution, dropwise adding 5mL of concentrated sulfuric acid, uniformly mixing, standing for 5min, placing into a water bath at 55 ℃, heating for 15min, taking out, naturally cooling for 5min to terminate the reaction, rapidly measuring, and measuring the absorbance (A) at 490nm by adopting a UV method. The absorbance measured for the crude polysaccharide sample solution was 0.288 as determined by the linear equation A =8.56c +0.1936 (R) 2 = 0.99497) calculating that the polysaccharide content in the crude polysaccharide sample is 81.09%, and the polysaccharide content in the whole herb of common sage is 5.51%.
Example 3 preparation of an anti-porcine pseudorabies virus preparation of Salvia plebeia polysaccharide
An anti-porcine pseudorabies virus preparation is obtained by dissolving the solid litchi polysaccharide obtained in example 1 in 0.1mol/L PBS buffer solution, and the concentrations of the litchi polysaccharide in the obtained solution are 200 mug/mL, 400 mug/mL and 600 mug/mL respectively.
Example 4 measurement of Activity of Salvia plebeian polysaccharide against porcine pseudorabies Virus
The concentration of the sage polysaccharide obtained in example 3 is 200 mug/mL and 400 mugTreatment of formulation at 600. Mu.g/mL 10 3.0 TCID 50 the/mL PRV virus solution was inoculated simultaneously with ST cells grown in advance as a dense monolayer, with drug treatment and virus inoculation controls and cell controls (24-well plates). Culture supernatants from (un) treated PRV infected cells were collected at 24 hours and 48 hours (freeze-thaw) and virus content was measured. The results are shown in table 1 and fig. 2, and about 50% of cytopathic effect of the PRV inoculated control cell wells can be seen in the litchi polysaccharide antiviral experiment ST cell inoculation 24 hours. No lesion appeared in the 400. Mu.g/mL and 600. Mu.g/mL dose groups, about 10-20% of the slight lesions appeared in the 200. Mu.g/mL dose groups, and the lichen polysaccharide control wells showed no visible change compared to the cell control wells. In the litchi grass polysaccharide antiviral experiment, after the ST cells are inoculated for 48 hours, the cells of the PRV inoculated cell control holes are completely floating. No lesions appeared in the 600. Mu.g/mL dose group, about 20% lesions were seen in the 400. Mu.g/mL dose group, and about 80% lesions were seen in the 200. Mu.g/mL dose group.
TABLE 1
Example 5 real-time fluorescent quantitative PCR of Pseudorabies Virus wild Virus SYBR-Green I
The common sage herb polysaccharide prepared in example 3 is treated with the preparation with the concentration of 200 mug/mL, 400 mug/mL and 600 mug/mL for 10 3.0 TCID 50 The PRV virus solution/ml was inoculated simultaneously with ST cells grown in advance as a dense monolayer, while drug treatment and virus inoculation controls and cell controls (24-well plates) were set up. Culture supernatants from (un) treated PRV infected cells were collected at 48 hours (freeze-thaw), viral genomes were extracted, and fluorescent quantitative PCR was determined, with triplicates. According to a 'internal standard curve' established by a real-time fluorescent quantitative PCR method of porcine pseudorabies virus wild virus SYBR-Green I in the literature, and a cp value of a quantitative sample is analyzed. The results are shown in Table 2, the concentration of the lychee polysaccharide can inhibit the replication of the pseudorabies virus, and the virus copy number of the cell pores is lower as the concentration of the lychee polysaccharide is increased.
TABLE 2
Example 6 protection of Lissapo polysaccharide against lethal challenge in mice
Virulent PRV strain 100LD at lethal dose 50 (SQ-20181210) the mice were challenged with the abdominal cavity, and the lychee polysaccharide (40 mg/kg body weight, 60mg/kg body weight, 80mg/kg body weight, 100mg/kg body weight, 120mg/kg body weight and 140mg/kg body weight) was used 24 and 48 hours before (after) challenge, respectively, and a challenge control group and a drug control group were established. Survival was observed daily. The results are shown in Table 3, wherein the body weight protection rate of 40mg/kg is 1/5, the body weight protection rate of 60mg/kg is 1/5, the body weight protection rate of 80mg/kg is 2/5, the body weight protection rate of 100mg/kg is 3/5, the body weight protection rate of 120mg/kg is 4/5, and the body weight protection rate of 140mg/kg is 4/5, so that the optimum dosage of the lychee seed polysaccharide is 120 mg/kg.
TABLE 3
The foregoing is only a preferred embodiment of the present invention, and it should be noted that, for those skilled in the art, various modifications and decorations can be made without departing from the principle of the present invention, and these modifications and decorations should also be regarded as the protection scope of the present invention.
Claims (1)
1. The litchi chinensis Sonn polysaccharide is used for preparing antiviral drugs, the virus is porcine pseudorabies virus, and the dosage of the litchi chinensis Sonn polysaccharide is 600 mug/mL.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110940901.9A CN113694080B (en) | 2021-08-17 | 2021-08-17 | Antiviral application of common sage herb polysaccharide |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110940901.9A CN113694080B (en) | 2021-08-17 | 2021-08-17 | Antiviral application of common sage herb polysaccharide |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113694080A CN113694080A (en) | 2021-11-26 |
CN113694080B true CN113694080B (en) | 2023-03-28 |
Family
ID=78652932
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110940901.9A Active CN113694080B (en) | 2021-08-17 | 2021-08-17 | Antiviral application of common sage herb polysaccharide |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113694080B (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101588004B1 (en) * | 2015-05-22 | 2016-01-26 | 임종식 | Attractive pill using Great plantain and pockmark cabbage and making method of it |
WO2016178490A2 (en) * | 2015-05-04 | 2016-11-10 | 재단법인 경기과학기술진흥원 | Pharmaceutical composition for preventing or treating gout and food composition for alleviating hyperuricemia, containing extract of salvia plebeia r. br. or fraction thereof |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101084990A (en) * | 2007-06-26 | 2007-12-12 | 陈朝银 | Preparation and application of sage polysaccharides and its esters |
CN105878369A (en) * | 2016-06-22 | 2016-08-24 | 江苏省农业科学院 | Chinese herbal compound for preventing and treating porcine epidemic diarrhea virus |
CN106473099A (en) * | 2016-10-12 | 2017-03-08 | 钟术光 | Functional food or alternative tea that effect improves |
CN108114021A (en) * | 2017-10-05 | 2018-06-05 | 湖南中医药大学 | A kind of pharmaceutical composition for being used to treat virus infected herpes |
CN108685980A (en) * | 2018-06-26 | 2018-10-23 | 江苏省农业科学院 | A kind of Chinese herbal compound preparation and its preparation method and application improving pig immunosuppressive condition |
CN109998012A (en) * | 2019-05-21 | 2019-07-12 | 平顶山学院 | Common Sage Herb general flavone extracts and the method for general flavone solid beverage preparation |
CN110403112A (en) * | 2019-07-17 | 2019-11-05 | 宁夏圣源春食品有限公司 | A kind of preparation method of bubble orange juice |
-
2021
- 2021-08-17 CN CN202110940901.9A patent/CN113694080B/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016178490A2 (en) * | 2015-05-04 | 2016-11-10 | 재단법인 경기과학기술진흥원 | Pharmaceutical composition for preventing or treating gout and food composition for alleviating hyperuricemia, containing extract of salvia plebeia r. br. or fraction thereof |
KR101588004B1 (en) * | 2015-05-22 | 2016-01-26 | 임종식 | Attractive pill using Great plantain and pockmark cabbage and making method of it |
Non-Patent Citations (3)
Title |
---|
Du, Hongxu,等.A flavone-polysaccharide based prescription attenuates the mitochondrial dysfunction induced by duck hepatitis A virus type 1.《PLoS One》.2017,第12卷(第4期),第1-14页. * |
Muhammad Akram,等.Heme oxygenase 1-mediated novel anti-inflammatory activities of Salvia plebeia and its active components.《J Ethnopharmacol.》.2015,第322-330页. * |
孙启文,等.荔枝草的化学成分及药理作用研究新进展.《中国药师》.2014,第17卷(第3期),第481-483页. * |
Also Published As
Publication number | Publication date |
---|---|
CN113694080A (en) | 2021-11-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1194752C (en) | Anti-virus Chinese medicine composition and preparation process thereof | |
CN102961439B (en) | Total flavone extract of Hyssopus officinalis, preparation method thereof and application thereof | |
CN101332255A (en) | Traditional Chinese medicine extract for preventing avian influenza and preparation method | |
CN102274314A (en) | Evergreen coccidian powder and preparation method thereof | |
CN101773527B (en) | Pinecone extractive of Yunnan Pinus and preparation method and medicinal application thereof | |
CN101669979B (en) | Artemisia scoparia extractive and production method and applications thereof | |
CN101596246B (en) | Smoked plum extractive and wild jujube seed extractive compound preparation as well as preparation method and application thereof | |
CN1872105A (en) | Application of holly and extractive in preparing medication for anti virus | |
CN101869595A (en) | Preparation method and quality detection method of liquorice and gall oral liquid | |
CN113694080B (en) | Antiviral application of common sage herb polysaccharide | |
CN101390956B (en) | Double coptis injection preparation method | |
CN103720932B (en) | One boar Chinese medicine composition and its preparation method and application | |
CN108272874A (en) | Chinese medicine preparation and preparation method thereof for laying hen | |
CN102813713B (en) | Rhizoma dryopteris crassirhizomae and fructus crataegi composition, preparation method and application of composition | |
CN105943820A (en) | Traditional Chinese medicine compound for resisting swine influenza and porcine reproductive and respiratory syndrome and extraction method thereof | |
CN103655544B (en) | The application of Jaceosidin in preparation prevention or the Fibrotic medicine for the treatment of chronic hepatic injury regulating liver-QI | |
CN115105502A (en) | Application of compound containing stephania plant alkaloid in preparation of feline infectious peritonitis medicine | |
CN101664441B (en) | Traditional Chinese medicine composition containing isatis leaf and application thereof | |
CN101564475B (en) | Application of Kegan Liyan Oral Liquid in preparing Chinese medicaments for preventing and treating bird flu | |
Aswar et al. | Effect of trigonelline on fertility in female rats | |
CN108524746B (en) | Traditional Chinese medicine composition for preventing and treating poultry cold | |
CN106237050A (en) | A kind of Chinese medicine compound of effective preventing and treating H1N1 and H3N2 swine flue and pig blue-ear disease and preparation method thereof | |
CN111481591A (en) | Veterinary traditional Chinese medicine coccidiosis oral solution and preparation method thereof | |
CN113975312B (en) | Antiviral drug composition, method for inhibiting in vitro virus activity and application | |
CN105106254A (en) | Anti-influenza loosestrife extract |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |